Pfizer will list its COVID-19 treatment Paxlovid at a price of $1,390 per five-day course when it soon hits the commercial market, the drugmaker confirmed to Axios.
Why it matters: Paxlovid’s new listed price, first reported by the Wall Street Journal, will be more than twice the $529 paid by the federal government, which until now has maintained the entire U.S. supply of the key antiviral medication.
Remember when the COVID vaccine came out and all the “don’t nationalize healthcare” mfs started making up strawmen to argue against because they have no idea what other people actually want for society? Pretty funny, huh?